Clinical trials: Oncologic
Cancer Pain
Unique Treatment of Oncology Pain in Advanced Cancer
This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to…
- Trial name
- UTOPIA-1 (NCT06533657)
- Testing
- Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- ZYUS Life Sciences Inc.
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Solid Tumours
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
The study design was an open-label Phase II pediatric clinical study. The purpose of Study X2203 was to identify any efficacy signal in subjects with the disease subtypes under study, when treated with pazopanib monotherapy.
- Trial name
- NCT01956669
- Testing
- Pazopanib
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
MTAP-deleted NSCLC
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).
- Trial name
- NCT06593522
- Testing
- anvumetostat
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 61 people
- Sponsor
- Amgen
Urothelial Carcinoma, Bladder Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia
- Trial name
- PRESERVE3 (NCT04887831)
- Testing
- Trilaciclib, Gemcitabine, Cisplatin
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 92 people
- Sponsor
- G1 Therapeutics, Inc.
Melanoma, Unresectable Metatstatic Cutaneous Melanoma
Use of 852A in Metastatic Cutaneous Melanoma.
Pilot study to test the efficacy of 852A administered intravenously up to 3 times per week for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.
- Trial name
- NCT00189332
- Testing
- 852A
- Where
- 8 sites in France, Germany and 1 more
- Volunteers
- 28 people
- Sponsor
- Pfizer
Gastroenteropancreatic Neuroendocrine Tumors
Community-based Neuroendocrine Tumor (NET) Research Study
The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot.
- Trial name
- NCT02730104
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ipsen
Prostate Cancer, Urine
Investigation of Urinary Biomarkers for the Detection of Prostate Cancer
The aim of this study is to investigate and possibly validate urinary biomarkers for prostate cancer. During this study the focus will be on aberrations of selected genes as prognostic or predictive value has been shown for these…
- Conditions
- Prostate Cancer, Urine, Liquid Biopsy
- Trial name
- URODETECT-WP2 (NCT05454371)
- Testing
- Colli-Pee UAS devices
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novosanis NV
Recurrent Glioblastoma
An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM
The purpose of this study is to test Y90 glass microspheres for people with recurrent brain cancer. Participation in this study will help researchers find the best dose for the treatment of the disease.
- Trial name
- ODYSSEY (NCT07867886)
- Testing
- Device: TheraSphere GBM treatment of TheraSphere GBM device
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 30 people
- Sponsor
- Boston Scientific Corporation
Metastatic Colorectal Cancer
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.
- Trial name
- NCT00339183
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 1,186 people
- Sponsor
- Amgen
Chemotherapy Induced Nausea and Vomiting
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.
- Trial name
- NCT01596413
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Prostatic Neoplasms
Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)
The purpose of this study is to assess the treatment patterns in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- REALIST-PRO (NCT02230059)
- Testing
- No Intervention
- Where
- 10 sites in Brazil
- Volunteers
- 382 people
- Sponsor
- Janssen Research & Development, LLC
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH
Advanced Malignant Tumors
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
- Trial name
- NCT06764771
- Testing
- BMS-986488, Adagrasib, Cetuximab
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 437 people
- Sponsor
- Bristol-Myers Squibb
Neoplasm
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Continuous dosing of BAY73-4506 in patients with advanced cancer
- Trial name
- NCT01117623
- Testing
- Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg
- Where
- 5 sites in United States
- Volunteers
- 86 people
- Sponsor
- Bayer
Non-Small Cell Lung Cancer
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) (Phase 1 portion) and to assess…
- Trial name
- NCT02944396
- Testing
- pemetrexed, nivolumab, paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- AbbVie
Oncology
Demonstration Of A Next Generation PET CT System
The intent of this evaluation is to obtain user feedback on device performance, user preference, image quality, workflow, and new device features, a necessary part of product development.
- Trial name
- NCT05122715
- Testing
- Additional PET/CT Scan
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- GE Healthcare
Squamous Cell Carcinoma of Head and Neck
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.
- Trial name
- NCT04144517
- Testing
- Nemvaleukin Alfa, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Mural Oncology, Inc
Carcinoma, Renal Cell
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
This was a first in human study of DFF332, a small molecule that targets a protein called HIF2α. By acting on HIF2α, DFF332 may be able to stop the growth of certain types of cancer.
- Trial name
- NCT04895748
- Testing
- DFF332, RAD001, PDR001
- Where
- 11 sites in United States, Czechia and 5 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies
- Trial name
- NCT07704658
- Testing
- Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive
- Where
- 2 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Rigel Pharmaceuticals